Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abbott, absorbable, Aileron, apari, Arisaph, ASA, ascending, Asian, aska, BA, back, Basilea, Baxalta, Baxter, Bentley, Biomedical, bioscience, BMS, Boehringer, bortezomib, BSLN, BVF, Carolina, Christopher, Claude, Daniel, DCGN, deCODE, DEUG, Dimension, dissolution, division, DMTX, Dohme, double, eleven, entrepreneur, Enumeral, error, exhausted, Foundation, fourteen, frame, FTE, fused, GenVec, grantee, Graybug, half, Hb, Hodgkin, Hoffman, HQH, HQL, ICS, inconsequential, Infinity, Ingelheim, Islay, ITAA, Japanese, Jazz, Julian, Keytruda, Kiritsy, Knopf, Kos, lab, Lampert, Lance, largest, Les, LeukoSite, leverage, lifted, LLP, lot, Lymphopoietin, Manchester, Margaret, Millennium, Mitsubishi, Moore, Nanovector, neck, nonpublic, Nordic, Nucala, Olmstead, Olstead, opportunistic, OS, Otsuka, Paratek, penetration, perfunctory, Pharmaceutica, PIPE, plc, pledge, preclude, pretax, printing, proceed, properly, ProScript, PRTK, PTI, regranted, relapse, repealed, replenished, reprice, repriced, Repricing, rest, Roxadustat, Sansome, seasoned, sentence, Servier, Sharp, sixty, spanning, spearheaded, spent, spin, Sr, steering, Strasbourg, strike, subdivided, subdivision, synthetic, Tanabe, TCM, tenure, Thibault, THQ, Thymic, topline, TSLP, underfund, Universit, unresponsive, unrestricted, unspecified, USA, USD, Velcade, visit, VP, Warp, winding, withhold, withholding, xi, xii, xiii, xiv
Removed:
eliminating, formal, paragraph, principle, ready, redeemable, travel
Filing tables
Filing exhibits
Related press release
PIRS similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATIONS UNDER SECTION 906
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2016 (the “Form10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: March 29, 2017 | /s/ Stephen S. Yoder | |||||
Stephen S. Yoder | ||||||
Title: | Chief Executive Officer and President | |||||
(principal executive officer) |